THU0547 Association of Asymptomatic Hyperuricemia and Endothelial Dysfunction in Psoriatic Arthritis
Authors: S.E. Ibrahim, A. Helmy, T. Youssef, M. Hassan, N. Farouk
Journal: Annals of the Rheumatic Diseases (2014)

<h3>Background</h3> Cardiovascular disease is an increasingly recognized contributor to excess morbidity and mortality in psoriatic arthritis (PsA). Atherosclerosis is a multifocal, immune-inflammatory disease affecting the medium and large arteries. There is growing evidence that, in addition to traditional risk factors, vascular wall inflammation plays a key role in the pathogenesis of vascular diseases and atherosclerosis. <h3>Objectives</h3> To examine the prevalence of suclinical atherosclerosis in patients with psoriatic arthritis to emphasize the potential role of serum uric acid on endothelial dysfunction, as an early predictor of atherosclerosis in psoriatic arthritis patients. <h3>Methods</h3> This study included 60 PsA patients as well as 60 age and sex matched healthy controls. Assay of serum uric acid, interleukin-6 (IL-6) and soluble intercellular adhesion molecule-1 (sICAM-1) was done for all patients and controls. Patients were subjected to psoriasis area severity index (PASI) and assessment of disease activity. Patients and controls underwent brachial flow-mediated dilatation (FMD) assessment by color duplex sonography to determine endothelial dysfunction as well as extracranial carotid arteries assessment by high-resolution B-mode ultrasound to measure the common carotid intima-media thickness (CIMT) and the detection of atheromatous plaques. <h3>Results</h3> PsA patients have a high significant difference in CIMT, FMD of the brachial artery and mean levels of serum uric acid compared to healthy controls (p&lt;0.001). PsA patients with hyperuricemia have a high significant difference in CIMT and FMD of the brachial artery than those with normal serum uric acid. Serum uric acid levels showed a high significant positive correlation with each of CIMT, disease duration, markers of inflammation (ESR, CRP, IL-6, sICAM-1),disease activity score in 28 joints (DAS 28) and PASI (r =0.71, 0.893, 0.956, 0.858, 0.853, 0.877, 0.907, 0.847, respectively, as p&lt;0.001). A high significant negative correlation was found betweenserum uric acid levels and FMD of the brachial artery as r = _0.634, p&lt;0.001. <h3>Conclusions</h3> Patients with PsA have a high prevalence of subclinical atherosclerosis dependent on serum uric acid, suggesting that chronic systemic inflammation and endothelial dysfunction appear to be the link between asymptomatic hyperuricemia and atherosclerosis. Therefore, proper control of serum uric acid may play a preventive role in the development of atherosclerosis in PsA patients. <h3>References</h3> Tomiyama H, Higashi Y, Takase B, Node K, Sata M, Inoue T,et al. Relationships among hyperuricemia, metabolic syndrome,and endothelial function. Am J Hypertens 2011;24:770–4. Contessa C, Ramonda R, Lo Nigro A, Modesti V, Lorenzin M, Puato M, et al. Subclinical atherosclerosis in patients with psoriatic arthritis: a case-control study. Preliminary data. Reumatismo 2009;25:298–305. Sattar N, McCarey DW, Capell H, McInnes IB. Endothelial dysfunction in psoriatic arthritis patients without clinically evident cardiovascular disease or classic atherosclerosis risk factors. Arthritis Rheum 2007;57:287–93. Sitia S, Tomasoni L, Atzeni F, Ambrosio G, Cordiano C, Catapano A, et al. From endothelial dysfunction to atherosclerosis. Autoimmun Rev 2010;9:830–4. Ramonda R, Lo Nigro A, Modesti V, Nalotto L, Musacchio E, Iaccarino L, et al. Atherosclerosis in psoriatic arthritis. Autoimmun Rev 2011;10:773–8. <h3>Disclosure of Interest</h3> : None declared <h3>DOI</h3> 10.1136/annrheumdis-2014-eular.2324